Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shigella sonnei-CRM9
- Development stage
- Phase 3
- Lead developer
- Samuel Jared Kushnick Immunology Laboratory
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
**Shigella sonnei-CRM9** is an investigational, monovalent glycoconjugate vaccine designed to prevent shigellosis caused by *Shigella sonnei*. It consists of the *S. sonnei* O-specific polysaccharide portion of lipopolysaccharide covalently linked to CRM9, a detoxified mutant diphtheria toxin carrier protein. Conjugation converts the polysaccharide antigen into a T-cell-dependent immunogen, promoting anti-lipopolysaccharide IgG responses, immunologic memory, and serotype-specific protection. The vaccine was evaluated by intramuscular administration in adults and young children and was included in a completed Phase 3 Israeli study of improved Shigella conjugate vaccines; it has not become a licensed product.
- Other names
- S. sonnei-CRM (9)S. sonnei-CRM9Shigella sonnei-CRM (9)Shigella sonnei-CRM9
02
Targets
Shigella sonnei O-specific polysaccharide
Beyond the preview
Go deeper on Shigella sonnei-CRM9.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shigella sonnei-CRM9.